Ginkgo's total revenue was $88 million, up from $31 million in the same period in 2020, an increase of 180%. Revenue from the company's foundry business contributed $44 million, up from $31 million from the first half of 2020. Biosecurity revenue was $44 million, relative to an original full-year projection of $50 million.

Highlights for the period included the launch of 11 new cell programs and an increased estimate for total new programs from 23 to 30 by the end of 2021. Ginkgo also said that several cell programs were delivered to customers or are nearing completion and are expected to contribute downstream value in 2021.

Aldevron, Ginkgo Bioworks achieve mRNA manufacturing breakthrough

Aldevron and partner Ginkgo Bioworks said that their strategic partnership has led to a manufacturing breakthrough for an enzyme often used in manufacturing...

Bolt Threads leverages Ginkgo Bioworks' protein manufacturing platform
Biotechnology company Bolt Threads has formed a partnership with Ginkgo Bioworks to leverage the company's engineering technology for the development...

Biogen, Ginkgo partner on enhanced AAV manufacturing for gene therapies
Biogen and Ginkgo Bioworks will collaborate to develop improved methods for manufacturing recombinant adeno-associated virus (AAV)-based vectors.

Ginkgo Bioworks nabs $1.1B to fight COVID-19 in U.S.
The U.S. International Development Finance Corporation has approved a loan of up to $1.1 billion to Ginkgo Bioworks, enabling it to expand biosecurity...

Totient advances anti-SARS-CoV-2 antibodies with funding, partnerships
Ginkgo Bioworks and artificial intelligence drug discovery firm Totient have partnered to identify antibodies effective against the novel coronavirus...